Back to top

Image: Bigstock

Here's Why You Should Retain Doximity Stock in Your Portfolio for Now

Read MoreHide Full Article

Key Takeaways

  • Doximity's active workflow prescribers rose 34% year over year, strengthening future monetization prospects.
  • AI Search gained traction, with 16 of the top 20 pharmaceutical companies purchasing programs.
  • Rising AI infrastructure costs, declining margins and subdued customer expansion remain key challenges.

Doximity DOCS is strengthening its growth prospects through accelerating physician engagement, expanding AI adoption and growing pharmaceutical demand for its AI Search platform. Partnerships and deeper health-system integration could further enhance its competitive position. However, modest revenue growth, rising AI infrastructure costs, lengthy commercialization timelines and subdued customer expansion remain key challenges.

Shares of this Zacks Rank #3 (Hold) company have lost 33.1% so far this year against the industry's 9% growth and the S&P 500 Index’s 5.9% rise.

Doximity, with a market capitalization of $5.47 billion, is a global specialty medical device company.

Zacks Investment Research
Image Source: Zacks Investment Research

DOCS’ bottom line is estimated to improve 1.3% over the next five years. Its earnings beat estimates in two of the trailing four quarters and missed twice, delivering a negative average surprise of 0.01%.

What's Driving DOCS’ Performance?

Accelerating Physician Engagement Strengthens Prospects: Doximity's expanding physician engagement provides a strong foundation for future revenue growth. Quarterly active workflow prescribers increased 34% year over year to record levels, with approximately half of the 1.8 million U.S. prescribers using its platform during the quarter. Growth was supported by telehealth, scheduling and increasing adoption of AI tools.

Management noted that physicians using the patient-context feature are generating roughly twice the usage, despite entering shorter prompts. As deeper engagement typically precedes monetization in Doximity's business model, the expanding user base could create meaningful opportunities to increase customer spending over the next several years.

AI Search Opens Access to a Larger Market: Doximity's AI Search product could expand its addressable market beyond traditional healthcare media and advertising. Sixteen of the top 20 pharmaceutical companies have purchased AI Search programs, while three additional companies are in the process.

Management described the product as an entry into the paid-search market, where U.S. pharmaceutical companies spend an estimated $14 billion annually. The offering is also generating eight-figure bookings, with management indicating that demand is largely incremental to existing business. Successful commercialization could diversify Doximity's revenue streams, deepen pharmaceutical relationships and provide a substantial growth opportunity as the product reaches more advertisers.

Partnership and DoseCheck Strengthen AI Differentiation: Doximity is strengthening its clinical AI proposition through differentiated medical content and medication-safety capabilities. Its DoseCheck verifier is designed to identify medication-dosing errors, addressing a critical concern around the reliability of AI-generated clinical answers.

The company has also integrated Wolters Kluwer's UpToDate, a widely used clinical reference supported by 7,600 physician authors. This partnership provides access to proprietary physician expertise that management believes is not readily available through general AI models. Together, these initiatives could improve physician trust, support wider adoption across healthcare systems and help Doximity differentiate its AI platform from competing general-purpose solutions.

What’s Weighing on DOCS Stock?

Rising AI Infrastructure Costs Could Pressure Margins: Doximity's rapid AI adoption is increasing infrastructure costs, creating a potential profitability challenge as the company scales its offerings. Adjusted gross margin declined to 88% in the fiscal second quarter from 92% in the previous quarter, primarily reflecting higher costs associated with clinician usage and AI investment.

Although management reported improving cost efficiency, the company expects continued investment in AI engagement, clinical content and health-system distribution during the second half of fiscal 2027. The company expects a full-year adjusted EBITDA margin of 47%, compared with 51% in the second quarter, indicating a lower EBITDA margin in the second half. Sustaining profitability will therefore depend on further infrastructure efficiencies and successful monetization of growing AI usage.

Slowing Net Revenue Retention: Doximity's customer expansion metrics suggest that monetization across its established client base remains relatively subdued. Net revenue retention was 103% overall and 106% among its top 20 hospital and pharmaceutical customers, indicating limited incremental spending compared with the previous year. Customers spending more than $500,000 annually accounted for 82% of revenues, but their number increased only 3% year over year to 124.

Management attributed some weakness to the slower revenue-growth environment and seasonal patterns, while expecting AI Search and improved market conditions to support future expansion. Until those drivers gain traction, subdued customer expansion could constrain revenue acceleration.

Estimate Trend

The Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $680.9 million, implying growth of 5.6% from the year-ago reported figure. The consensus mark for adjusted EPS is pinned at $1.34, indicating a decline of 11.8% from the previous year’s recorded level.

In the past 30 days, DOCS’ earnings estimate for fiscal 2027 has improved 1 cent.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .

Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 138.6%.

Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.

Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%.

Cardinal Health, currently carrying a Zacks Rank of 2, reported a first-quarter fiscal 2027 adjusted EPS of $3.26, which surpassed the Zacks Consensus Estimate by 11.64%. Revenues of $67.51 billion beat the Zacks Consensus Estimate by 0.8%.

CAH has an estimated long-term earnings growth rate of 10.1%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 13.79%

Published in